Everyone who knows us closely knows how much Canvasalus is investing in developing new high-CBG strains. In fact, since last year, our efforts have led to the development of two new varieties (Gerona (8-9% CBG) and Gerovita (11-13% CBG)) which we are happy to inform you are already in the first registration cycle in the National Register of new hemp varieties.
Cannabigerol, which in the last period is beginning to receive the due attention and to take its place in the market, is certainly one of the most interesting cannabinoids even at a medical level. Two new papers, in fact, are added to the list of experiments that try to confirm how CBG can boast various therapeutic and beneficial effects for many living beings. Although hundreds of cannabinoids have been identified, its interest has grown particularly due to its anti-inflammatory properties.
The first study that we want to bring to your attention, sees the participation of several universities and research centers; in particular we can mention that of Oxford (English) and the Hebrew University (Israeli). This preclinical experimentation has shown how innovative synthetic derivatives of CBG possess strong analgesic and anti-inflammatory properties; in particular, it has been highlighted how the metabolism of mice subjected to a diet rich in fat is much better if they have been treated with one of these derivatives (HUM-234).
You can find the complete article below
Another interesting paper from an English university (Nottingham) that we want to bring to your attention is not exclusively about CBG, but a combination of derivatives attributable to different cannabinoids, including THC, CBD and CBG. This study demonstrates that there is a significant number of preclinical evidence to support the efficacy of cannabinoids in the treatment of colitis, thus providing for other supporting clinical trials.